Company Secretary resigns; new Company Secretary and Chief Operating Officer appointed
Ms. Shivali Aggarwal resigns as Company Secretary & Compliance Officer (personal reasons).
- Resignation
- Ms. Shivali Aggarwal resigns as Company Secretary & Compliance Officer (personal reasons)
- New Company Secretary Appointment
- Mr. Ashwani Singh Bisht appointed Company Secretary & Compliance Officer, 12 years experience
- New COO Appointment
- Mr. Arvind Gannimitta appointed Chief Operating Officer, Ph.D. in Pharmaceuticals, 26 years experience
- Effective Date
- 30th September 2026
What was approved
The Board met on 30th September 2026 and approved three personnel changes, all effective the same day.
Exit
- Ms. Shivali Aggarwal resigned as Company Secretary & Compliance Officer, citing personal reasons in her letter dated 11th August 2026.
- Earlier disclosure said her exit would be effective on or before 12th October 2026; the Board has now made it effective from 30th September 2026.
Appointments
- Mr. Ashwani Singh Bisht as Company Secretary & Compliance Officer, designated Key Managerial Personnel, on whole-time employment. He is a member of ICSI with over 12 years of professional experience, including more than 5 years in corporate secretarial and compliance functions, across listed and unlisted companies.
- Mr. Arvind Gannimitta as Chief Operating Officer, Senior Management Personnel, on whole-time employment. He holds a Ph.D. in Pharmaceuticals and has over 26 years of experience in pharmaceutical operations and manufacturing.
How to read this
The compliance officer position has been filled on the same date the outgoing officer leaves, so there is no gap in the statutory role. The COO appointment adds a dedicated operations head with a pharmaceutical manufacturing background. These are management and governance changes; no financial terms were stated in the update.
Also from Sai Parenterals
Acquisition of 60% stake in Prathyak Laboratories R&D facility completed for Rs. 15 crore
5 Oct 2026
Monitoring agency report flags IPO proceeds deviation up to 10%; no shareholder approval
3 Oct 2026
Sai Parenterals officials to meet investors/analysts at Hyderabad facilities on 14 October 2026
1 Oct 2026
More numbers
- Bisht professional experienceover 12 years
- Bisht secretarial/compliance experiencemore than 5 years
- Gannimitta pharma operations experienceover 26 years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.